These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Licensing of protein products from the milk of transgenic animals. Validation for pathogen removal--a strategy. Wright G, Colman A, Cottom D, Williams M. Dev Biol Stand; 1996 May; 88():269-76. PubMed ID: 9119150 [No Abstract] [Full Text] [Related]
23. Viral safety of biological products and the concept of validation. Horaud F. Dev Biol Stand; 1996 May; 88():19-24. PubMed ID: 9119135 [No Abstract] [Full Text] [Related]
24. Final report on the safety assessment of AloeAndongensis Extract, Aloe Andongensis Leaf Juice,aloe Arborescens Leaf Extract, Aloe Arborescens Leaf Juice, Aloe Arborescens Leaf Protoplasts, Aloe Barbadensis Flower Extract, Aloe Barbadensis Leaf, Aloe Barbadensis Leaf Extract, Aloe Barbadensis Leaf Juice,aloe Barbadensis Leaf Polysaccharides, Aloe Barbadensis Leaf Water, Aloe Ferox Leaf Extract, Aloe Ferox Leaf Juice, and Aloe Ferox Leaf Juice Extract. Cosmetic Ingredient Review Expert PanelCosmetic Ingredient Review, Washington DC 20036, USA.. Int J Toxicol; 2007 May; 26 Suppl 2():1-50. PubMed ID: 17613130 [Abstract] [Full Text] [Related]
26. Safety assurance for biologics manufactured in mammalian cell cultures: a multitiered strategy. Chen D. Adv Biochem Eng Biotechnol; 2014 Mar; 139():167-83. PubMed ID: 23719711 [Abstract] [Full Text] [Related]
27. Detection of adventitious viruses in biologicals--a rare occurrence. Nims RW. Dev Biol (Basel); 2006 Mar; 123():153-64; discussion 183-97. PubMed ID: 16566443 [Abstract] [Full Text] [Related]
28. Introduction to the issues: recently developed methods for characterizing cell lines. Kozak RW. Dev Biol Stand; 1992 Mar; 76():21-4. PubMed ID: 1478337 [Abstract] [Full Text] [Related]
29. Cost-effectiveness of new blood safety technologies. AuBuchon JP. Dev Biol (Basel); 2000 Mar; 102():211-5. PubMed ID: 10794108 [Abstract] [Full Text] [Related]
30. Quality of biotechnological products: viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. ICH Harmonised Tripartite Guideline. Dev Biol Stand; 1998 Mar; 93():177-201. PubMed ID: 9737396 [No Abstract] [Full Text] [Related]
31. Strategies to avoid virus transmissions by biopharmaceutic products. Werz W, Hoffmann H, Haberer K, Walter JK. Arch Virol Suppl; 1997 Mar; 13():245-56. PubMed ID: 9413543 [Abstract] [Full Text] [Related]
32. Issues of biological assays for viral vaccines. Lee CK. Dev Biol Stand; 1996 Mar; 88():41-7. PubMed ID: 9119161 [Abstract] [Full Text] [Related]
33. Pathogen safety of manufacturing processes for biological products: special emphasis on KOGENATE Bayer. Lee DC, Miller JL, Petteway SR. Haemophilia; 2002 Mar; 8 Suppl 2():6-9. PubMed ID: 11966845 [Abstract] [Full Text] [Related]
35. Approaches in the risk assessment of genetically modified foods by the Hellenic Food Safety Authority. Varzakas TH, Chryssochoidis G, Argyropoulos D. Food Chem Toxicol; 2007 Apr; 45(4):530-42. PubMed ID: 17275157 [Abstract] [Full Text] [Related]
36. Future development of harmonized guidelines. Hayakawa T. Dev Biol Stand; 1996 Apr; 88():331-2. PubMed ID: 9119158 [No Abstract] [Full Text] [Related]
37. Sourcing pharmaceutical, biological and medical components from livestock in the United States. Detwiler LA. Dev Biol Stand; 1996 Apr; 88():243-5. PubMed ID: 9119145 [Abstract] [Full Text] [Related]